Expert Operational Team
Fredrik Lehmann
PhD, MBA, Chief Executive Officer
Before joining Sound Bioventures in September 2023, Fredrik was a venture partner at Industrifonden. Prior to this, he held senior executive and operational roles at several biotech companies, including Oncopeptides (head of research and CMC), Recipharm (General Manager) and EpiEndo (CEO and CMC). He has also founded several life science companies including OT Chemistry, which was acquired by Recipharm in 2015. Fredrik has a Ph.D. from Göteborg University and an executive MBA from Stockholm School of Economics. In addition, he has published over 50 peer reviewed articles and 25 patent applications.
Klara Acs
PhD, Chief Development Officer
Klara holds a PhD in Molecular Biology and has more than 10 years of experience from drug development in Associate Principal and Translational Science Director roles at Medivir, Sprint Bioscience and Oncopeptides. She has experience in nonclinical pharmacology, clinical translational science and real-world evidence generation. She holds a PhD in Molecular Biology.
Tobias L. Agervald
MD, PhD, Senior Advisor -Consultant
Dr. Tobias L. Agervald, MD, PhD, is an associate professor and internationally recognized researcher in experimental and clinical nephrology and endocrinology. He completed his PhD at Harvard Medical School and Uppsala University and a postdoctoral fellowship at Indiana University. As CEO of Guard Therapeutics and former Senior Medical Director in Clinical Development at Astellas Pharma, he brings extensive global drug development experience across early and late clinical stages. A recognized Key Opinion Leader, he has authored more than 100 high‑impact scientific publications, received multiple research awards, and served on advisory boards for numerous pharmaceutical companies.
Antonio
Bermejo Gómez
PhD, Head of CMC - Consultant
Antonio holds a PhD in Organic Chemistry. He has extensive, 14 years work experience in pharma industry at Sprint Bioscience, Oncopeptides. and at Synartro. Dr. Bermejo Gómez owner of Abego Pharma Insights AB.
Elisabeth Augustsson
Head of Regulatory Affairs - Consultant
Owner of Restracom AB. Extensive experience from executive roles in Regulatory Affairs in pharma and Biotech sector.
Sina Saidiakbarzadeh
(MSc Pharmacy), Head of QA - Consultant
Over 10 years Quality Assurance experience within GMP and GDP from both big and small pharma companies.
Anneli Hällgren
PhD, Head of Toxicology - Consultant
Owner of Prekliniska byrån. Extensive experience from preclinical toxicology from big pharma and small Biotech.
Board of Directors – world-class excellence in biotech entrepreneurship
Krim Talia
PhD, 3T Invest Founder & Owner, Startups founder & CEO Chairman
Dr. Talia holds a Phd from the Stockholm School of Economics, and Postdoctoral Fellow at the Department of Economics at Harvard University. Dr. Talia has also served as Vice President Health and Lifescience at RISE - Research Institutes of Sweden. Dr. Talia has extensive experience as a founder and CEO for Startups, and Scaleups such as Nanologica AB and Mindler Group. He has also been the CEO at Sting, a world leading Incubator and Accelerator in Stockholm. Dr. Talia is co-founder of several successful companies in multiple industries. He is the founder and sole owner of 3TInvest, one of Sweden’s most active seed round Investors (including Norrsken Evolve Fund, Pinecone Ventures).
Tobias Larsson Agervald
MD, Phd, Nephrology and Internal medicine specialist, Board member
Dr. Tobias L. Agervald, MD, PhD, is an associate professor and internationally recognized researcher in experimental and clinical nephrology and endocrinology. He completed his PhD at Harvard Medical School and Uppsala University and a postdoctoral fellowship at Indiana University. As CEO of Guard Therapeutics and former Senior Medical Director in Clinical Development at Astellas Pharma, he brings extensive global drug development experience across early and late clinical stages. A recognized Key Opinion Leader, he has authored more than 100 high‑impact scientific publications, received multiple research awards, and served on advisory boards for numerous pharmaceutical companies.
Johan Kördel
PhD, Managing partner at Sound Bioventures, Board member
Prior to founding Sound Bioventures, Johan was a Senior Partner at Lundbeckfonden Ventures where he worked for 12 years, and led investments and served as a Board director in companies including: Acacia Pharma (Euronext: ACPH, sold to Eagle Pharmaceuticals), Amplyx (sold to Pfizer), Bonesupport (OMX: BONEX), Celladon (Nasdaq: CLDN), Curzion (sold to Horizon), Reneo Pharma (Nasdaq: RPHM), River Vision (sold to Horizon), Syntaxin (sold to Ipsen), VHSquared (sold to Sorisso Pharma) and Ziarco (sold to Novartis).Johan worked in the biopharmaceutical industry for 20 years. He is a co-founder of three biotech companies.
Fredrik Lehmann
PhD, MBA, CEO at Renity Therapeutics, Board member
Before joining Sound Bioventures in September 2023, Fredrik was a venture partner at Industrifonden. Prior to this, he held senior executive and operational roles at several biotech companies, including Oncopeptides (head of research and CMC), Recipharm (General Manager) and EpiEndo (CEO and CMC). He has also founded several life science companies including OT Chemistry, which was acquired by Recipharm in 2015. Fredrik has a Ph.D. from Göteborg University and an executive MBA from Stockholm School of Economics. In addition, he has published over 50 peer reviewed articles and 25 patent applications.